Anticipating Diagnostic Demands to Avoid Costly Delays in Gene Therapy Development
- Clarifying the evolving FDA expectations for companion diagnostics in gene therapy programs
- Identifying strategies to mitigate delays caused by late-stage CDx requirements
- Understanding how regulatory ambiguity impacts patient selection and program timelines